Home
Search results “Data mining drug development companies”
Big data aids drug development
 
01:54
Pharmaceutical companies partner on big data project to inform drug development
BenevolentBio's Professor Jackie Hunter on Transforming Drug Discovery at Disrupt London 2016
 
21:01
Professor Jackie Hunter of BenevolentBio chats with Sarah Buhr about using AI to trawl the global ocean of scientific and medical data for pharmaceutical R&D.
Views: 891 TechCrunch
Myths and Urban Legends in Drug Development Part II: Pre Clinical Myths
 
18:27
Drs. Michelle Higgin and Lisa Lallos talk to hundreds of newly formed biotech companies every year and have the opportunity to hear their creative strategies for building value on extremely lean budgets. Many of those ideas are ground breaking, but some are based on misconceptions that lead to costly delays and missed investment opportunities. Knowing how to side step these landmines will help streamline the development path but also offer some new strategies. During the presentation, they share some truths, myths and legends spanning drug development–preclinical, CMC, clinical, regulatory and program management. This video series will help early biotech companies avoid these potential pitfalls while providing alternatives paths to IND and clinical studies.
Intel ®Pharma Analytics Platform | Intel Business
 
02:58
Intel's AI platform for pharmacological clinical trials. For more information please contact [email protected] Subscribe now to Intel Business on YouTube: http://intel.ly/intelitcenteryt About Intel Business: Get all the IT info you need, right here. From data center to devices, the Intel® Business Center has the resources, guidance, and expert insights you need to get your IT projects done right. Connect with Intel Business: Visit Intel Business's WEBSITE: http://intel.ly/itcenter Follow Intel Business on TWITTER: https://twitter.com/IntelITCenter Follow Intel Business on LINKEDIN: https://www.linkedin.com/showcase/intel-business Follow Intel Business on FACEBOOK: https://www.facebook.com/IntelBusiness Intel ®Pharma Analytics Platform | Intel Business https://www.youtube.com/intelitcenter
Views: 1180 Intel Business
Role of Epidemiological Data within the Drug Development Lifecycle: A Chronic Migraine Case Study
 
57:46
A public health seminar recorded on October 17, 2011. Epidemiologists working in the pharmaceutical industry use the principles of descriptive epidemiology in addition to applied concepts and methods to assess the impact, use and effects of drugs in the population and in clinical trial settings. As there is a wide spectrum of data needs and requirements during any drug's lifecycle, a summary, including a real-world example, of the epidemiological data and methods utilized specifically during clinical development phase is timely. This presentation will provide a case study describing how epidemiological data was used to support the registration of onabotulinumtoxinA (BOTOX®, Allergan, Inc., Irvine, CA, USA) for treatment of headaches in adults with chronic migraine.
Views: 743 UCI Open
Stanford Webinar - Using Electronic Health Records for Better Care
 
46:58
In the era of Electronic Health Records, it’s possible to examine the decision outcomes made by doctors and identify patterns of care by generating evidence from the collective experience of patients. In this webinar, Stanford Assistant Professor Nigam Shah will show you methods that transform unstructured patient notes into a de-identified, temporally ordered, patient-feature matrix. Four use-cases will be examined, which use the resulting de-identified data matrix to illustrate the learning of practice-based evidence from unstructured data in electronic medical records.. This webinar will teach you the practical value of: •Monitoring for adverse drug events •Identifying drug-drug interactions •Profiling the safety of off-label drug usage •Generating practice-based evidence for difficult-to-test clinical hypotheses. Presented by the Stanford Center for Professional Development (http://scpd.stanford.edu)
Views: 9185 stanfordonline
XLDB2011 Drug Discovery in the Era of Big Data
 
30:10
Speaker: Gregory McAllister (Novartis) XLDB 2011 http://www-conf.slac.stanford.edu/xldb2011 Copyright 2011 Stanford University This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. http://creativecommons.org/licenses/by-nc-nd/3.0/
Views: 235 XLDBConf
Vineti mission: Software and Cure for Cancer
 
18:56
Backed by GE Ventures, Mayo Clinic Ventures, and DFJ, the Vineti team brings together a hybrid of experts in user-centric, regulated industry software and analytics development, as well as commercial therapeutics development and manufacturing. Vineti was founded to solve the key challenges patients, medical providers, pharmaceutical companies and regulators face in the delivery and commercialization of personalized medicine. Recently, U.S. Food and Drug Administration (FDA) approved cutting edge cancer therapy based on cell and gene Therapy. This talk will present Vineti mission and software product offering focused around Cell and Gene therapy. Vineti has already invested in building an Armenian software product development office. This talk will also cover role of Vineti Armenia. About the Speaker Razmik is a leading business software executive. He is currently CTO and Cofounder for Vineti. He was former CTO for EMC Documentum product family, leading Enterprise Content Management platform and solutions for Fortune 5000. Razmik was one of the original designers of Documentum platform. He was a founding member of Documentum team; starting with handful of people, growing to become a leading force in Enterprise Content Management industry with IPO in 1996 and eventual acquisition by EMC in 2003 for $1.7 Billion. Razmik is author of several patents and coauthor of several technical books. He is also investor and advisors to multiple high tech companies.
Views: 290 CSE AUA
Mining the FDA Adverse Event Reporting System with Oracle Empirica Signal
 
57:11
Learn how to identify safety and pharmacovigilance signals by data mining FAERS with Oracle's Empirica Signal. -- Ever since the European Union (EU) introduced new legislation that requires life sciences companies to proactively detect, prioritize, and evaluate safety signals, there has been an increased interest, not only from sponsors and CROs in the EU, but globally, in pharmacovigilance systems that can assist with the signal management process. Please join Perficient's Chris Wocosky, an expert in signal detection and management, for this video in which she discussed how your organization can use Empirica Signal, Oracle's state-of-the-art signal detection system to data mine the existing FDA Adverse Event Reporting System (FAERS) to determine safety signals. This video will help you to better understand how this solution can be used in daily pharmacovigilance activities. To view this webinar in its entirety, please visit: https://cc.readytalk.com/r/7ekwxbm7q33t&eom Stay on top of Life Sciences technologies by following us here: Twitter: http://www.twitter.com/Perficient_LS Facebook: http://www.facebook.com/Perficient LinkedIn: http://www.linkedin.com/company/165444 Google+: https://plus.google.com/+Perficient SlideShare: http://www.slideshare.net/PerficientInc
Views: 4360 Perficient, Inc.
Drug Repurposing for Rare Diseases Conference - Lightning Talk 5
 
05:34
To celebrate Rare Disease Day 2016, Findacure organised its annual scientific conference to create a forum that brings together patient groups, clinicians, researchers, biotech companies, and the pharmaceutical industry to discuss the role that drug repurposing can play in the future of rare disease treatment. As part of the conference, there was a section inviting delegates to share 5 minute lightning talks of their work on drug repurposing. In this talk, Jane Reed from Linguamatics describes the company's text mining solution, which has been used by researchers at Shire Pharmaceuticals to develop insights into the association of genetic variation with severity phenotypes, in Hunter Syndrome patients. If you would like to support the work of Findacure, why not donate to the charity via http://uk.virginmoneygiving.com/charities/findacure
Views: 91 Findacure
GrossTo Net Predictive Modeling - Pharmaceutical
 
05:24
Gross-To-Net (GTN) Predictive Modeling is a web-based forecasting application developed by Inferential Designs for small to mid-size pharmaceutical companies that market their products into government and/or commercial channels with which they contract. In addition to user developed forecasts, the model features multiple pre-defined forecasting options using statistical and quantitative methods that provide guidance to the user with a single click of the mouse. All options render instant results and provide strong emphasis on those calculations most meaningful to a managed markets analysis.
Targeted Marketing With Data Mining: Finding Consumers More Accurately Part 2
 
09:58
Louise Keely is the Intellectual Capital Director at The Cambridge Group where she is involved in management consulting and developing growth strategies for clients that are driven by a superior understanding of profitable demand. In this video, she shares how they have been able to find consumers more accurately and actively using Salford Systems' data mining tools.
Views: 170 Salford Systems
Automated Drug Safety Processing
 
23:41
Presentation at "SwissText 2016" 08.06.2016 in Winterthur. http://www.swisstext.org René Haltiner, Michel Plüss, Simon Felix, Jonas Schwammberger, Michael Kalt, Manfred Vogel - Automated Drug Safety Processing Abstract: We describe the architecture and choice of algorithms for an automated processing of Adverse Drug Reports (ADR). Pharmaceutical companies are legally obligated to monitor adverse drug reactions and report them to the national drug regulatory authorities. Due to the variety of data sources and formats these reports are mainly manually processed and mapped onto the standardized CIOMS form (Council for International Organizations of Medical Sciences). Key features of this form are recurring elements like health care professionals, drugs, diseases and patients. Our objective is the automatic processing of these documents which by regulation have to be written in English. In order to process free text we use OCR, named entity recognition and other NLP tools. Attributes like medical tests, findings and treatments are strongly interlinked and can be represented by an ontology. The processed data is validated by machine learning algorithms and finally exported to the CIOMS form.
Views: 474 Swiss Text
Prescription  Data Mining  and  You
 
02:41
Created on March 27, 2009 using FlipShare.
Views: 1233 HCFAMA
Linguamatics How Agios Uses Text Mining Webinar Preview
 
05:32
Agios continues to advance drug programs in the clinic. For Agios, text mining plays a key role in these advances, providing critical information for decision-making at different stages in the drug discovery process, from bench to bedside. All pharmaceutical companies need an efficient and compliant system to manage safety data in a responsible way. To accomplish this, Agios is in the process of implementing an Adverse Event Reporting System (AERS). The AERS will support the collection of appropriate data as per FDA/global regulations. Natural language processing (NLP) is being used in multiple places in the workflow at Agios: to mine AE reports, extract case-data from call center records, and assist with initial coding of reported events and WHO drugs. Agios are using data generated by Linguamatics NLP text mining to help understand the progression of AEs in ongoing clinical trials.
Views: 36 BioITWorld
Medical Coding with MedDRA
 
01:00:34
Learn about the best practices for medical coding using MedDRA, a global dictionary used by companies for regulatory activities. -- MedDRA is a global dictionary used by companies for regulatory activities. The dictionary, complete with clinically validated terminology, is used to classify adverse event information related to the use of drugs, devices, and other therapies. Coding the data to a standard set of MedDRA terms enables health authorities and the life sciences industry to more readily exchange and analyze data. MedDRA is considered the international standard for adverse event classification. However, while the data volume and standardization capabilities offered by the dictionary can provide significant benefits, the multi-axial design and data specificity can introduce considerable challenges that could lead to the inaccurate classification of data. Join BioPharm Systems' Dr. Rodney Lemery, vice president of safety and pharmacovigilance, and Caroline Halsey, director of project management, EMEA, for this free one-hour webinar that will explore the best practices for medical coding using MedDRA. To view this webinar in its entirety, please visit: http://www.biopharm.com or https://cc.readytalk.com/r/fqfuit5ql7qh. Twitter: http://www.twitter.com/BioPharmSystems Facebook: http://www.facebook.com/BioPharmSystems LinkedIn: http://www.linkedin.com/companies/biopharm-systems-inc Google+: https://plus.google.com/104105608638786200757
Views: 14662 BioPharmSystems
Using JReview to Analyze Clinical and Pharmacovigilance Data in Disparate Systems
 
57:31
Learn how JReview can be used to analyze clinical and pharmacovigilance data. -- Sponsors and CROs naturally rely on various clinical and safety systems from a multitude of software vendors. However, continuously accessing disparate sources for the reporting, analysis, and monitoring of data can be a treacherous undertaking, if you don't have a solution that connects to them right out of the box. That's where JReview comes in. For almost two decades, life sciences companies, research organizations, in addition to the government, have relied on JReview for the comprehensive analysis and monitoring of clinical and pharmacovigilance data. In this webinar, we discussed: • The features and benefits of JReview, including the new functionality in v10.0 (e.g., risk-based monitoring analytics reporting on the clinical data itself, etc.) • Benefits of using JReview for: o Reporting and query of your clinical data o Supplying internal and/or external users/sponsors information o Providing a secure way for your internal users and/or sponsor users to access the clinical data • Examples of how customers use JReview with OC/RDC • The implementation process and options • Your own questions and challenges To view this webinar in its entirety, please visit: http://www.perficient.com/Thought-Leadership/On-Demand-Webinars/2014/Using-JReview-to-Analyze-Clinical-and-Pharmacovigilance-Data-in-Disparate-Systems Stay on top of Life Sciences technologies by following us here: Twitter: http://www.twitter.com/Perficient_LS Facebook: http://www.facebook.com/Perficient LinkedIn: http://www.linkedin.com/company/165444 Google+: https://plus.google.com/+Perficient SlideShare: http://www.slideshare.net/PerficientInc
Views: 6869 Perficient, Inc.
How a collaborative approach is key to faster drug development
 
07:28
The centre of innovative medical discoveries. The Medicines Discovery Catapult is a new, national centre of applied R&D expertise to promote and support innovative, fast-to-patient drug discovery in the UK through collaborative projects across the community. MDC work with biopharma companies of all sizes, translational researchers, technology experts, patient groups and the contract research and finance sectors to help transform great ideas into commercial products and services for the wider health and wealth of the country. By developing and validating new ways of discovering new medicines, and promoting key talent and expertise across sectors, MDC can help the UK maintain its heritage position as a global leader in this key industry. Find out more with Adrian Dawkes of PharmaVentures, as he discusses the significance of having patients in the centre of drug discovery with Chris Molloy, CEO of MDC.
Insilico Medicine Stands Out at 2015 GTC Emerging Companies Summit
 
01:39
While deep learning was the topic of many conversation at last week’s 2015 GPU technology conference (GTC), the CEO of one start-up spoke passionately about using fast GPUs to fight cancer and push the human lifespan well beyond the generally-agreed ceiling of 120 years. Insilico Medicine, a Baltimore MD bioinformatics company, is one of 12 companies recognized as the hottest GPU-powered startups in the US. While other startups in the GTC Emerging Companies Summit have business models focused on self-driving cars, gaming, animation, or 3D imaging, Insilico Medicine is the only start-up using GPU technology to fight age-related diseases such as cancer or Alzheimer’s. "We live in a very exciting time when information technology is converging with biotechnology", said Alex Zhavoronkov, PhD, the CEO of Insilico Medicine. "We developed a bioinformatics platform and strategy to tackle humanity's greatest challenge - aging and age-related diseases and we're honored to be recognized by NVIDIA as a promising GPU-powered startup." Until the early 1990s, biology and related fields required very little experience with computers. Now, however, the vast amount of DNA and molecular data generated from the Human Genome Project and labs around the world have made high-powered computer analysis necessary. Because GPU-accelerated computing is the fastest way to analyze data, Insilico Medicine has received a great deal of attention in recent weeks from pharmaceutical companies and investors. Medical researchers agree GPU computing and computer science will play a key role in finding cures for age-related diseases and extending the human lifespan. “Aging is humanity's most complex and daunting medical problem and it has defeated us for too long, said Dr. Aubrey de Grey, a gerontology expert and the Chief Science Officer of the SENS Research Foundation. “We will overcome it with a trifecta of new technologies, new insights - and new data analysis tools, an area at which Insilico Medicine promises to be at the forefront.“ The 11 GPU-powered companies joining Insilico Medicine include Artomax, Ersatz Labs, FluiDyna, GeekSys, Intempora, NE Scientific, Pythia Systems, QM Scientific, Redshift Rendering Technologies, Replica Labs, and SYSTAP. "To analyze how cancer cells respond to certain treatments, you must run drug scoring algorithms on high-end big data computer systems." said Zhavoronkov. “and no one can manage this work more effectively than our team of experts in both computer science and bioscience.” About Insilico Medicine Insilico Medicine, Inc. is a Baltimore-based company utilizing advances in genomics and big data analysis for in silico drug discovery and drug repurposing for aging and age-related diseases. The company utilizes the GeroScope™, OncoFinder™ , Pathway Cloud Intelligence™ and PharmAtlas™ packages for aging and cancer research, pursues internal drug discovery programs, and provides services to pharmaceutical companies. If you have any questions about the science of aging, bioinformatics, or Insilico Medicine's plan to use GPUs in anti-aging research and drug discovery, please call (443) 451- 7212 or visit: www.insilicomedicine.com.
Impress Your Fresher Job Interviewer
 
07:14
How to attend Freshers Jobs interview Video
Views: 4164441 Neha Sharma
Lasell Speaks: Open Source Drug Discovery
 
01:50
To learn more and register for the event, click here: www.lasellalumni.org/bradner
Views: 122 Lasell College
Is Open Source Drug Discovery Practical? (2/4)
 
52:32
"Is Open Source Drug Discovery Practical?" WHO/TDR HQ, Geneva, September 19th, 2013 Summary article: http://www.who.int/tdr/news/2013/odd/en/ Video 2 of 4 - see below for details Rob Don (DNDi) presentation: DNDi aims to get drugs into the clinic. Much work is pre competitive, much of it is not open because of contractual obligations, but the aim is ultimately to provide the final medicine inexpensively. Whether we should aim for programmed obsolescence of PDPs, i.e. a different, more sustainable model. The ongoing challenge of meeting R&D costs. Concerns of osdd: i) incentives - open source drug discovery would mainly be outside the industrial sector, while academia sector is not typically focussed on proper drug discovery programs. Publications can be incentives to take part. Could modify the tenure process to acknowledge drug discovery programs. An Idea: Collective postgrad degrees on a drug discovery program. An incentive is to see there is a guaranteed path through drug development to the patient. The osdd process needs leadership, meaningful scientific questions, rapid turnaround and momentum. Lluis Ballell (GSK Tres Cantos) presentation: Work with PDP partners. Differences between open and traditional methods of drug discovery. Tres Cantos helps through provision of infrastructure and people, managed by the OpenLab Foundation, funding through EU and Wellcome Trust. Also contribute to data sharing, e.g. major antimalarial data set, through ChEMBL. Works with WIPO to try to reconcile openness with the IP framework that binds them. A search for balance: Tres Cantos patents operate on the principle that anything arising from research on NTDs should be royalty free. Comment from Mat Todd that the provision of the open data helped secure government funding for the OSM project because of the quality of the starting points, and that the personal input from scientists in GSK (which are personal, so expensive) have helped. Chas Bountra (Structural Genomics Consortium, University of Oxford) presentation: Problem of massive duplication of effort in drug discovery research, e.g. in kinase research. SGC works on novel human proteins only. All outputs are published immediately and given away. Funded by pharma: 8-9 companies each contributing $8M. Generates much collaborative work. The transparency generates trust. Disclosure of data does not prevent traditional journal publication. Working on bromodomain inhibitors, e.g. with Jay Bradner. SGC released the structure of the inhibitor, stimulating a large amount of activity, including industrial activity and VC funding. Drug discovery as a lottery because of high attrition rates, arising from poor target validation prior to the clinic. The secrecy is wasting financial and human resources. Idea is to create a new PPP to generate clinical candidates that will be taken to patients in the absence of IP, as a "knowledge creation endeavor". Proof of clinical mechanism (POCM). By avoiding IP one can access the best academics quickly. Targets selected by industry. Involvement of patient groups. Industry later develops proprietary assets. This open approach as the only way to really solve big issues such as Alzheimer's. beta-amyloid. 29 years of research on this one target, $30Bn spent, no candidates. Tom Bombelles (WIPO) presentation: The role of WIPO to support IP systems that deliver societal benefits. IP not an end in itself, but rather as a tool to support innovation. 20th Century IP system has developed powerful and useful products but is perhaps not delivering in the way it used to. Not perfect, e.g. in not delivering benefits to all sectors of society equally. In the area of NTDs: WIPO:Research as an open innovation (not open source) initiative. Database - members can advertise the availability of IP assets including services such as screening, to those engaging in research in this area. Allows for transfer of IP assets in order to try to stimulate activity. Patents are intended to make information public so that others can use the information. In return, the inventor gets exclusive rights. The IP system makes the transfer of proprietary knowledge possible. But should exist within a multitude of models. Patents are one part of IP, but there are more components. Example of facilitation: UCSF working with Merck on schistosomiasis through a WIPO agreement to help navigate the Valley of Death. WIPO Research has 33 collaborations at the time of this meeting. New knowledge in a WIPO Research project: patenting is encouraged, but royalty-free licensing is required.
Views: 221 OSDDMalaria
LIBER-C4C Event September, 2013 - A Workshop on Text & Data mining for Data Driven Innovation
 
05:49
LIBER organised a workshop, with the support of C4C, on the future potential and challenges of Text and Data Mining (TDM) at the British Library in London. The Workshop looked at the potential of TDM to support European research and industrial activity/new startup companies. A list of distinguished speakers made a convincing case for TDM. As one speaker said, the Web is useless without it. Check the event summary on the LIBER website: http://www.libereurope.eu/blog/the-perfect-swell-at-the-british-library
Morgan Stanley May Lead Palantir IPO After a Decade of Courtship
 
03:17
Sep.04 -- After a decade vying with Wall Street rivals, Morgan Stanley is emerging as the adviser-of-choice for Palantir Technologies Inc., Peter Thiel’s secretive data-mining and visualization venture. Bloomberg's Lizette Chapman reports on "Bloomberg Technology."
Views: 1187 Bloomberg Technology
Big Data and Marketing Conference, Jerome Couturier (3H Partners)
 
14:10
Jerome Couturier, chairman of 3H Partners challenged delegates to adopt a Big Data approach throughout the business process and in particular in the decision-making phase. He presented various ways that companies can gain value and build a competitive advantage by the use of big data in decision-making, demonstrating the example of a large pharmaceutical and of a leading sports equipment manufacturer.
Clinical Trials Technology: Bringing it all together with PAREXEL®
 
02:16
PAREXEL® Informatics, Corporate Vice President Ken Faulkner discusses his company’s unique Perceptive® MyTrials solution. All along your new drug’s development path, PAREXEL® Informatics has technological innovations that make the process faster, more precise, more trackable, and more productive. PAREXEL® leads the industry in creating integrated platforms and applications specifically designed to improve how biopharmaceutical companies perform clinical trials, control and share data, track and report patient outcomes, and manage regulatory information worldwide. Technology: another example of how PAREXEL® is bringing it all together. Learn more at: https://www.parexel.com/solutions/informatics/ See how PAREXEL brings it all together: Consulting: https://www.youtube.com/watch?v=giZotfdHRhw Clinical Research Services: https://www.youtube.com/watch?v=5EHb6Qd5JNQ
Views: 5000 PAREXEL International
Alexander Steudle (Certara): D360 - The Pharmaceutical Data Analytics and Scientific Platform
 
05:32
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Combining legacy brands including Pharsight, Simcyp, Tripos and Certara, these technologies are used across the drug development life cycle. Pharmacologists, toxicologists, biostatisticians, pre-clinical scientists, chemists, geneticists, and other scientists use Certara software to inform key safety and efficacy decisions, including target identification and optimization, dosing, trial design, target validation, compound triaging, comparison with competitor compounds, and mechanistic drug performance. Certara’s D360 R&D data platform solves data challenges faced by scientists and IT staff throughout biopharmaceutical organizations by integrating and leveraging the large amount of diverse scientific data generated by sponsor companies and their outsourced partners to optimize crucial decisions.
Views: 246 ChemAxon
FDA Use of Big Data in Modeling and Simulations
 
02:54
According to Jeffry Florian, PhD, Review Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration (FDA), the use of big data in modeling and simulations is dependent upon the stage of drug development: pre-clinical, clinical and post-marketing. Dr. Florian discusses the types of questions posed by the FDA during each stage of drug development. For more information, visit http://www.npcnow.org/issues/comparative-effectiveness-research
Views: 397 npcnow
Pipeline covered with Cortellis for Competitive Intelligence
 
00:53
Pipeline identification team focus on drug development, they look at financial filings, annual reports, tech transfer company portfolios, Biotech networks and academic journals. Pharma websites pipelines are one of the best sources reviewed and analyzed to confirm stages in later development. Learn more at: http://cortellis.thomsonreuters.com/cortellis_for_you/competitive_intelligence/
Views: 356 Thomson Reuters
On Diversity, Complexity, and Regularization in Ensemble Models - Part 1
 
12:38
SF Bay ACM Data Mining Event: On Diversity, Complexity, and Regularization in Ensemble Models http://www.sfbayacm.org/?p=2164 See also Giovanni's book on the same subject: from Amazon ($27.76) http://www.amazon.com/Ensemble-Methods-Data-Mining-Predictions/dp/1608452840/ref=sr_1_1?ie=UTF8&qid=1295920281&sr=8-1 from publisher, PDF for $20.00 http://www.morganclaypool.com/action/doSearch?target=article&searchText=Giovanni+Seni&filter=all&x=0&y=0 Abstract: The discovery of ensemble methods is one of the most influential developments in Data Mining and Machine Learning in the past decade. These methods combine multiple models into a single predictive system that is more accurate than even the best of its components. The use of ensemble methods can provide a critical boost to existing systems addressing the hardest of industrial challenges -- from investment timing to drug discovery, from fraud detection to recommendation systems -- where predictive accuracy is vital. This talk, based on a recently published book by the speaker, offers a concise introduction to this breakthrough topic. After a sketch of the major concerns in predictive learning, the talk will give an overview of regularization, a key concept driving the superior performance of modern ensemble algorithms. It then takes a shortcut into the heart of the popular tree-based ensemble creation strategies using recent developments from the frontiers of statistics, where research efforts are now focused to explain and harness the mysteries of ensembles. Biography: Giovanni Seni is a Senior Scientist with Elder Research, Inc. (ERI) and directs ERI's Western office. As an active data mining practitioner in Silicon Valley, he has over 15 years R&D experience in statistical pattern recognition, data mining, and human-computer interaction applications. He has been a member of the technical staff at large technology companies, and a contributor at smaller organizations. He holds five US patents and has published over twenty conference and journal articles. His book with John Elder, "Ensemble Methods in Data Mining -- Improving accuracy through combining predictions", was published in February 2010 by Morgan & Claypool. Giovanni is also an adjunct faculty at the Computer Engineering Department of Santa Clara University, where he teaches an Introduction to Pattern Recognition and Data Mining class.
Tonestra token introduction
 
01:28
INTRODUCING ...Tonestra Tonestra is the healthcare and biometric blockchain project that is designed to transform information sharing and record keeping in healthcare industry Tonestra offers the first complete blockchain healthcare project where scientist and healthcare receivers can have their data securely stored for utilization by healthcare practitioners. Tonestra gives: 1. Healthcare data contributors absolute right to own their data and how they use it 2. Contributors financial gain and benefits by providing access to industry users, such as biotechnology research companies and medicinal drug developers for a payment 3. open access for The development of an ecosystem where all users continuously work for the development of the platform for the benefit of all The tonestra token(tnr) Tonestra token TNR will be the dynamic currency fuel payment unit which will power the system platform. The tokens will be attached to data storage and in transmitting information across the Tonestra network and ecosystem. Five million Tonestra TNR tokens have beeen created and their Token Standard is Ethereum ERC20 smart contract Be a part of this project by investing in the THE TONESTRA token. Tonestra token is listed and presently traded on the crex24 exchange( crex24.com) and will soon be listed on other major cryptocurrency exchangers for more info visit www.tonestra.com
Views: 6888 Tonestra TNR token
SIS Int Research, Data Mining ROI, Consumer Sentiment Towards Marketing (RBDR--1/27/12)
 
02:49
Sponsored by: SSI http://www.surveysampling.com/forms/RBR-banner Today: 1) SIS' new report says data mining will be improving ROI. 2) The Notre Dame & Socratic Technologies' Index of Consumer Sentiment Towards Marketing is positive for the first time in 25 years.
Revolutionising Healthcare: Systems Biology & P4 Medicine | Dr Leroy Hood
 
01:05:37
Systems Medicine and Proactive P4 Medicine - Transforming healthcare through scientific wellness: A personal view P4 Medicine: Predictive, Preventive, Personalized and Participatory. The two major objectives of P4 Medicine are to quantify ‘scientific wellness' and demystify disease. Systems biology will revolutionize the practice of healthcare in the coming decades. Medicine today is largely reactive; we wait until a person is sick and then treats a disease, with varying levels of success. A medical revolution will emerge from the convergence of systems biology and the digital revolution’s ability to create consumer devices, generate and analyse “big data” sets and deploy this information through business and social networks. --- Dr. Lee Hood’s outstanding contributions have had a resounding effect on the advancement of science since the 1960s. Throughout his career, he has adhered to the advice of his mentor, Dr. William J. Dreyer: “If you want to practice biology, do it on the leading edge, and if you want to be on the leading edge, invent new tools for deciphering biological information.” He was involved in the development of five instruments critical for contemporary biology—namely, automated DNA sequencers, DNA synthesizers, protein sequencers, peptide synthesizers, and an ink jet printer for constructing DNA arrays. These instruments opened the door to high-throughput biological data and the era of big data in biology and medicine. He helped pioneer the human genome program—making it possible with the automated DNA sequencer. Under Hood’s direction, the Human Genome Center sequenced portions of human chromosomes 14 and 15. In 1992, Hood created the first cross-disciplinary biology department, Molecular Biotechnology, at the University of Washington. In 2000, he left the UW to co-found Institute for Systems Biology, the first of its kind. He has pioneered systems medicine the years since ISB’s founding. Hood has made many seminal discoveries in the fields of immunology, neurobiology and biotechnology and, most recently, has been a leader in the development of systems biology, its applications to cancer, neurodegenerative disease, and the linkage of systems biology to personalized medicine. In addition to his ground-breaking research, Hood has published 750 papers, received 36 patents, 17 honorary degrees and more than 100 awards and honors. He is one of only 15 individuals elected to all three National Academies—the National Academy of Science, the National Academy of Engineering, and the Institute of Medicine. Hood has founded or co-founded 15 different biotechnology companies including Amgen, Applied Biosystems, Rosetta, Darwin, Integrated Diagnostics, Indi Molecular and Arivale. UCD Twitter: http://twitter.com/ucddublin UCD Facebook: https://www.facebook.com/universitycollegedublin UCD Instagram: http://instagram.com/ucddublin UCD Homepage: http://www.ucd.ie
Introduction to Medicines Discovery Catapult
 
32:22
Medicines Discovery Catapult CEO, Chris Molloy, tells us about the Catapult and how it hopes to put patients at the heart of drug discovery.
e-Therapeutics CFO says 2012 will be an exciting year for the company
 
09:42
8/11/11 Daniel Elger, CFO at e-Therapeutics (LON:ETX), tells Proactive Investors that 2012 is the year when the meaningful data starts to come through after this year's successful recapitalisation. Daniel explains how the e-Therapeutics proprietary network pharmacology platform works and it's advantages in drug discovery.
Translating a Trillion Data Points into Therapies and New Insights into Disease
 
58:01
There is an urgent need to take what we have learned in our new “genome era” and create Dr. Butte's lab at the University of California, San Francisco builds and applies tools that convert trillions points of molecular, clinical, and epidemiological data -- measured by researchers and clinicians over the past decade and now commonly termed “big data” -- into diagnostics, therapeutics, and new insights into disease. Dr. Butte, a computer scientist and pediatrician, will highlight how publicly-available molecular measurements to find new uses for drugs including drugs for inflammatory bowel disease and cancer, discovering new diagnostics for complications during pregnancy, and how the next generation of biotech companies might even start in your garage.
Views: 1614 Dreamforce Video
Why investors are considering ImmuPharma, ahead of phase III data release
 
46:45
We reveal the full City investor briefing to provide further insight into ImmuPharma’s drug platform. We focus predominantly on Lupuzor’s phase III lupus trial and also introduce our cancer and peptide programmes. Hear from ImmuPharma's Tim McCarthy, Chairman, Robert Zimmer, Chief Scientific Officer and Dimitri Dimitriou, Chief Executive Officer
Views: 2221 ImmuPharma
Rx-360 White Paper on Traceability Data Exchange and Architecture
 
42:27
Rx-360 is a consortium being developed by volunteers from the Pharmaceutical and Biotech industry which includes their suppliers. The purpose is to enhance the security of the pharmaceutical supply chain and to assure the quality and authenticity of the products moving through the supply chain. The individuals developing this concept are working in the best interest of patients. We are a non-profit organization with the mission to create and monitor a global quality system that meets the expectations of industry and regulators that assures patient safety by guaranteeing product quality and authenticity throughout the supply chain.
Views: 56 Rx-360 Consortium
Drug repurposing
 
01:26:59
Broadly speaking, diseases can be targeted using drugs that are either small molecules (such as aspirin or acetylsalicylic acid), or larger molecules like proteins (such as Avastin or bevacizumab). Most pharma companies have enormous libraries of compounds that never made it as drugs for the intended purpose - according to some reports, only 1 in 1000 molecules make it to the final stage where they are approved by the FDA for human use. Some of those that did not meet approval may have also gone through clinical trials but were rejected due to not meeting the expected levels of efficacy. So what can one do with this arsenal of molecules that never made the cut? Enter drug repurposing. In all likelihood, some of the abandoned small molecules - the 99.9% that didn't make it to the market for the intended disease, can be reviewed for their effect on the diseases listed in Goal 6 of the MDG 2015.
Views: 185 Tilde Cafe
Top 10 NSE/Bse Listed Biotech Companies In India
 
04:23
1. BIOCON Ltd http://www.biocon.com/ 2.Panacea Biotec Ltd http://www.panaceabiotec.com/ 3. Alpa Laboratories Ltd http://www.alpalabs.com/ 4. Celestial Biolabs Ltd http://celestialbiolabs.com/ 5. Camson Bio Technologies Ltd http://www.camsonbiotechnologies.com/ 6. Vivo Bio Tech Ltd http://www.vivobio.com/ 7. Saamya Biotech (India) Ltd http://www.saamyabiotech.com/Saamya-India/index.html
Views: 1352 Patel Vidhu
Human genome’s frontier may hold keys to new drugs, Genome, Research, Human Genome Project
 
03:28
Human genome’s frontier may hold keys to new drugs, Genome, Research, Human Genome Project The development of new drugs currently focuses on just 60 percent of potential drug targets, a new study indicates. The study, which builds on extensive data analysis conducted using super computers—a technique called data mining—has examined huge amounts of literature within the health and medical sciences and other evidence sources in order to identify both the most and least studied proteins for drug targets. Of the 20,000 proteins the researchers included in the study, they conclude that around 8,000 of these have not been mapped and studied by researchers or pharmaceutical companies. The study is believed to be the first to provide a comprehensive and useful picture of all the proteins that can be used to develop new drugs. The combination of categorization and rankings [of proteins] works almost like a treasure map for drugs. Since the 1990s, researchers affiliated with the Human Genome Project have tried to map the human genome. In 2014, through the project Illuminating the Druggable Genome, the National Institutes of Health Common Fund took steps toward mapping the genes in the human genome that code for proteins. The researchers initially believed that more than 100,000 genes coded for proteins, but the mapping showed that only around 20,000 do. The drugs available today relate to less than 1,000 drug targets. According to Søren Brunak of the from the Novo Nordisk Foundation Center for Protein Research, the potential of drug design based on these proteins is almost exhausted, and therefore exploring new territory is important. “We have used highly advanced computer analysis of data to shed light on the parts of the human genome that are rarely researched. We can see that they hold great potential, and we hope the analysis can motivate drug researchers to do some pioneer work. This may prove significant to future drug innovation,” says Brunak. Dysfunctional proteins that have been damaged by genetic flaws cause many diseases. The vast majority of drugs aimed at treating these diseases work to prevent these proteins from becoming active. Proteins with great potential are often referred to as drug targets and may, after extensive clinical trials, be approved for use as drugs. Studying and identifying proteins that are instrumental in diseases is a vital part of developing new drugs. The new study shows that researchers have yet to subject 40 percent of all potential drug proteins to thorough and prioritized study. As part of their work, the researchers also divided the 20,000 proteins into four categories and ranked their potential as future drugs. The combination of categorization and rankings works almost like a treasure map for drugs. To find new drugs, make ‘libraries’ from DNA The research could also pave the way for new so-called repositioning opportunities, where already approved drugs can be tested on new factors. This means that proteins in drugs only approved for one therapy area could be tested for the treatment of other diseases. The researchers report their findings in the journal Nature Reviews–Drug Discovery. The analysis is based on research collaboration among the NIH National Center for Advancing Translational Sciences; Novo Nordisk Foundation Center for Protein Research; the Faculty of Health and Medical Sciences, University of Copenhagen; the University of New Mexico, the University of Miami; the European Bioinformatics Institute; and the Icahn School of Medicine at Mt. Sinai. Source: University of Copenhagen
Views: 6 thanh kids
Data Mining Full Tutorial
 
10:26
Generally, data mining (sometimes called data or knowledge discovery) is the process of analyzing data from different perspectives and summarizing it into useful information - information that can be used to increase revenue, cuts costs, or both. Data mining software is one of a number of analytical tools for analyzing data. It allows users to analyze data from many different dimensions or angles, categorize it, and summarize the relationships identified. Technically, data mining is the process of finding correlations or patterns among dozens of fields in large relational databases. Continuous Innovation Although data mining is a relatively new term, the technology is not. Companies have used powerful computers to sift through volumes of supermarket scanner data and analyze market research reports for years. However, continuous innovations in computer processing power, disk storage, and statistical software are dramatically increasing the accuracy of analysis while driving down the cost. Example For example, one Midwest grocery chain used the data mining capacity of Oracle software to analyze local buying patterns. They discovered that when men bought diapers on Thursdays and Saturdays, they also tended to buy beer. Further analysis showed that these shoppers typically did their weekly grocery shopping on Saturdays. On Thursdays, however, they only bought a few items. The retailer concluded that they purchased the beer to have it available for the upcoming weekend. The grocery chain could use this newly discovered information in various ways to increase revenue. For example, they could move the beer display closer to the diaper display. And, they could make sure beer and diapers were sold at full price on Thursdays. Data, Information, and Knowledge Data Data are any facts, numbers, or text that can be processed by a computer. Today, organizations are accumulating vast and growing amounts of data in different formats and different databases. This includes: operational or transactional data such as, sales, cost, inventory, payroll, and accounting nonoperational data, such as industry sales, forecast data, and macro economic data meta data - data about the data itself, such as logical database design or data dictionary definitions . Many More Videos: http://topsolution.webnode.com
Views: 267 Sajedur Rahaman
Data Science Community Interview with Deepthi Pullarkat - Experience in the Pharma Industry
 
01:29
Deepthi shares an interesting case study on one of her pharma clients, and how a well-thought visualization can help convince a whole team of a theory.
Views: 111 CrowdANALYTIX
Establishing causality in microbiome studies
 
01:03:06
Establishing causality in microbiome studies Views: Total views: 218, (142 Live, 76 On-demand) Category: WALS - Wednesday Afternoon Lectures Runtime: 01:03:06 Description: NIH Director's Wednesday Afternoon Lecture Series Rob Knight develops and uses state-of-the-art computational and experimental techniques in his lab to ask fundamental questions about the evolution of the composition of biomolecules, genomes, and communities in different ecosystems, including the complex microbial ecosystems of the human body. His laboratory subscribes to an open-access scientific model, providing free, open-source software tools and making all protocols and data publicly available in order to increase general interest in and understanding of microbial ecology, and to further public involvement in scientific endeavors more generally. The Knight Lab has produced many of the software tools and laboratory techniques that enabled high-throughput microbiome science, including the QIIME pipeline and UniFrac. Knight is co-founder of the Earth Microbiome Project, the American Gut Project, and the company Biota, Inc., which uses DNA from microbes in the subsurface to guide oilfield decisions. His work has linked microbes to a range of health conditions including obesity and inflammatory bowel disease; has enhanced our understanding of microbes in environments ranging from the oceans to the tundra; and has made high-throughput sequencing techniques accessible to thousands of researchers around the world. For more information go to https://oir.nih.gov/wals Author: Rob Knight, Ph.D., Professor, Departments of Pediatrics and Computer Science and Engineering, University of California at San Diego Permanent link: https://videocast.nih.gov/launch.asp?23587
Views: 686 nihvcast
Living Heart Project ~ Using High Performance Computing in the Cloud to Save Lives
 
30:41
In this video from the Stanford HPC Conference, Burak Yenier from UberCloud and Francisco Sahli from Stanford University presents: Living Heart Project ~ Using High Performance Computing in the Cloud to Save Lives. "Cardiac arrhythmia can be a potentially lethal side effect of medications. During this condition, the electrical activity of the heart turns chaotic, decimating its pumping function, thus diminishing the circulation of blood through the body. Cardiac arrhythmia, if not treated with a defibrillator, can cause death within minutes. Before a new drug reaches the market, pharmaceutical companies need to check for the risk of inducing arrhythmias. Currently, this process takes years and involves costly animal and human studies. In this project, the Living Matter Laboratory of Stanford University developed a new software tool enabling drug developers to quickly assess the viability of a new compound. This means better and safer drugs reaching the market to improve patients’ lives. During this session we will look at how High Performance Computing in the Cloud is being used to prevent severe side effects and save lives." Learn more: https://insidehpc.com/2017/12/video-wolfgang-gentzsch-award-winning-stanford-living-heart-project/ and http://hpcadvisorycouncil.com Sign up for our insideHPC Newsletter: http://insidehpc.com/newsletter
Views: 188 RichReport
Success Story of Biostatistician, Breaking The Glass Ceiling, PHARMA-STATS
 
01:40
Presenting Nirali Meh­ta & HER STORY Owner and Founder of ­PHARMA-STATS "­Ideas Are Nothing Wit­hout Action."­ I begin with my profe­ssional career in the­ corporate world with­ an ambition to move ­up the ladder in 2003­ with Wockhardt then ­Torrent Pharmaceutica­ls as a Bio-statistic­ian. In 2013 I had to­ resign due to my fam­ily responsibility. H­owever, never content­ at being the backgro­und. I decided to start ne­w venture that would ­enable me to grow pro­fessionally without c­ompromising family re­sponsibility. I soon ­begin a completely ne­w venture PHARMA-STAT­S in unexplored terri­tory of pharmaceutica­l statistics that inv­olved a unique and customiz­ed job-oriented cours­e that help FRESHER s­tatisticians to gain ­expertise, enhance cr­edibility as a techni­cal professional and ­provide the relevant ­practical and theoret­ical knowledge of the­ domain. The fact tha­t the training module­s are designed and de­livered by experience­d biostatisticians. Having work for more ­than 10 years in phar­maceutical industry I­ have a clear picture­ of the requirements ­of a variety of organ­izations, helping me ­to impart the exact s­kills including techn­ical, communication a­nd administrative req­uired by pharmaceutic­al companies. With many years of our experience we fill the gap between Industry and academy by moulding fresh students into confident persona with our unique training. The unique selling pr­oposition (USP) was t­hat students would no­t have to be trained ­after placement by th­eir departments in la­rge companies making ­them industry ready a­nd highly absorb able­. This created win-wi­n situation for both ­the students and comp­anies where these stu­dents were being plac­ed by PHARMA-STATS. To date we can boost ­up more than 70 stude­nts in the corporate ­world of pharmaceutic­als taking home hands­ome packages, thanks ­to the industry frien­dly training provided­ by me. I dream of a skilled ­training institute fo­r students especially­ from rural or econom­ical weaker sections ­to provide them world­ class opportunities.­ Here, students from ­economically weaker s­ituations are provide­d facility like waver­ of fees as well paym­ent after getting job­. This is done with t­he cross subsidizing ­the cost of these cla­sses by taking semina­rs and workshops for ­employee of pharmaceu­ticals and free lanci­ng statistical consul­tancy work. For this ­kind of unique dedica­tion to society, I ha­ve been awarded by ‘L­ions club of Gujarat ­for Outstanding Contr­ibution in a area of ­Statistics’ in 2014. Being a woman entrepr­eneur I had to work d­oubly hard to ensure ­a successful career w­ith family responsibilities. I w­as working from 6am t­o 12am or sometimes m­idnights, every singl­e day. I have learned­ a lot from business ­friends, employees & ­customers. Business is hard. You­ need much more than ­hard work. You need t­o learn everyday and ­prove that you are gi­ving to the world the­ right value or contr­ibution. You need to ­make it happen. Ideas­ are nothing without ­action. I love to challenge t­he challenges & find ­out of the box soluti­ons. My this approach­ helps me to manage e­verything and of cour­se with complete fami­ly support. PHARMA-STATS­ Corporate Training Ce­nter & Statistical Consultancy Se­rvices for Clinical S­tudies Ahmedabad, Gujarat, I­ndia Company Site: ­http://www.pharma-sta­ts.in LinkedIn Company Page­: https://www.linkedin.­com/company/pharma-st­ats
Views: 1484 PHARMA -STATS
Data DC Visualization: The Panama Papers: Visualizing International Corruption
 
01:15:09
The Panama Papers represent one of the world's largest data leaks in history: 11.5 million records exposing a system that enables crime, corruption, and wrongdoing, hidden by secretive offshore companies. Over 400 journalist members of the International Consortium of Investigative Journalists (ICIJ) worked for a year mining and investigating the data stored in a Neo4j graph database. This resulted in the resignation of the PM of Iceland, Supreme Court hearings for Pakistan's PM, the arrest of people money laundering for Mexican drug cartels, and plenty of more investigations and regulatory reforms. In this talk, Ryan Boyd will demonstrate how Neo4j graph database powered this investigation, showing queries and visualizations highlighting the relationships between offshore companies, corporate officers, law firms and addresses. He'll use the Neo4j Sandbox to show you how you too can dive into the data which has been opened up by the ICIJ for the world to investigate. You'll learn to write basic Cypher queries for finding nodes, relationships, and paths. We'll also provide an intro to how Graph Algorithms in the APOC open source library can help better understand the networks in the Panama Papers data. About Ryan Boyd Ryan is a San Francisco-based software engineer, authNZ geek, data geek and graph geek. He's Director of Developer Relations for Neo4j, an open source graph database which powers connected data analysis in data journalism, cancer resource, and some of the world's top companies. Prior to Neo4j, he was Head of Developer Relations for Google Cloud Platform and worked on over 20+ different APIs and developer products during his 8 years at Google. Ryan is the author of "Getting Started with OAuth 2.0," published by O'Reilly. He no longer skydives now that he has a young daughter, but enjoys the adventures of sailing and cycling.
Views: 150 Data Community DC